Neuroinflammation in Parkinson's Disease
Introduction
Neuroinflammation In Parkinson'S Disease represents a key pathological mechanism in neurodegenerative . This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.
Overview
Mermaid diagram (expand to render)
Triggers of Neuroinflammation in PD
Alpha-Synuclein as a DAMP
Pathological alpha-synuclein aggregates act as Damage-Associated Molecular Patterns (DAMPs) that activate innate immune responses: [@jo2026]
Direct microglial activation via TLR2 and TLR4
NLRP3 inflammasome activation leading to caspase-1 activation
Complement system activation with synaptic pruning
Release of pro-inflammatory cytokines that spread pathology [1]Mitochondrial DAMPs
mtDNA release from damaged mitochondria
N-formylated peptides from mitochondrial
ATP release from compromised neuronsOxidative Stress
Reactive oxygen species (ROS) from dopaminergic metabolism
Reactive nitrogen species (RNS) from nitric oxide
Lipid peroxidation products (4-HNE, MDA)Microglial Activation in PD
Morphological Changes
Mermaid diagram (expand to render)
Classical (M1) vs Alternative (M2) Activation
| Phenotype | Markers | Secreted Factors | Function | [@jahan2026]
|-----------|---------|------------------|----------| [@she2026]
| M1 (Classical) | CD16, CD32, CD86, iNOS | TNF-α, IL-1β, IL-6, ROS | Pro-inflammatory, cytotoxic | [@wang2025]
| M2 (Alternative) | CD206, Arg1, YM1, Fizz1 | IL-4, IL-10, BDNF, IGF-1 | Anti-inflammatory, neuroprotective | [^6]
In PD, microglia predominantly adopt the M1 phenotype, contributing to chronic neuroinflammation [2]. [^7]
Pro-inflammatory Cytokines
| Cytokine | Source | Effect in PD | Therapeutic Target | [^8]
|----------|--------|--------------|-------------------| [^9]
| TNF-α | Microglia, astrocytes | Neuronal apoptosis, BBB disruption | Etanercept, Infliximab | [^10]
| IL-1β | Microglia | Promotes alpha-syn aggregation | Anakinra, Canakinumab | [@tansey2022]
| IL-6 | Microglia, astrocytes | Neurotoxicity, gliosis | Tocilizumab | [^12]
| IFN-γ | T cells, NK cells | Microglial priming | Anti-IFN-γ antibodies | [@wang2021]
Chemokines
| Chemokine | Receptor | Role in PD | [@kouli2018]
|-----------|----------|------------|
| CXCL12 (SDF-1) | CXCR4 | Microglial recruitment |
| CCL2 (MCP-1) | CCR2 | Monocyte infiltration |
| CCL3 (MIP-1α) | CCR1/5 | Neuroinflammation amplification |
NLRP3 Inflammasome in PD
The NLRP3 inflammasome is a key driver of neuroinflammation in PD:
Mermaid diagram (expand to render)
Evidence in PD
NLRP3 is activated in PD substantia nigra
ASC specks (inflammasome markers) are elevated in PD brain
Genetic variants in NLRP3 are associated with PD risk
Inhibition of NLRP3 is neuroprotective in models [3]Genetic Factors Affecting Neuroinflammation
PD Risk Genes with Inflammatory Functions
| Gene | Function | Effect on Neuroinflammation |
|------|----------|---------------------------|
| LRRK2 | Kinase | Enhances microglial activation |
| GBA | Lysosomal enzyme | Impairs autophagy, increases inflammation |
| TREM2 | Microglial receptor | Alters microglial response |
| CD33 | Immune receptor | Increases inflammation |
| HLA-DRB1 | MHC class II | Antigen presentation |
LRRK2 and Neuroinflammation
LRRK2 mutations (G2019S, R1441C/G/H) enhance microglial activation:
- Increased pro-inflammatory cytokine production
- Enhanced ROS generation
- Accelerated disease progression in models [4]
Blood-Brain Barrier Dysfunction
Neuroinflammation contributes to BBB breakdown in PD:
TNF-α and IL-1β disrupt tight junctions
MMP-9 activation degrades basement membrane
Peripheral immune cell infiltration (T cells, monocytes)
Leakage of plasma into brain parenchymaTherapeutic Strategies
Anti-inflammatory Approaches
| Target | Drug Class | Examples | Status |
|--------|-----------|----------|--------|
| NLRP3 | Small molecule inhibitors | MCC950, Dapansutrile | Preclinical |
| IL-1β | IL-1 receptor antagonist | Anakinra | Phase II |
| TNF-α | Monoclonal antibodies | Etanercept | Phase II |
| COX-2 | NSAIDs | Ibuprofen, Celecobex | Observational |
| CSF1R | Receptor antagonists | PLX3397 | Phase I |
Microglia-Targeting Strategies
TREM2 modulation - enhance phagocytosis
PPAR-γ agonists - shift to M2 phenotype
Minocycline - broad microglial inhibition (failed in trials)
CX3CR1 antagonists - reduce microglial recruitmentBiomarkers of Neuroinflammation
| Biomarker | Sample | Level in PD |
|-----------|--------|-------------|
| TNF-α | CSF, plasma | Elevated |
| IL-1β | CSF, plasma | Elevated |
| IL-6 | CSF, plasma | Elevated |
| NfL | Plasma | Elevated |
| YKL-40 | CSF | Elevated |
| sTREM2 | CSF | Variable |
Disease Progression Model
Mermaid diagram (expand to render)
Cross-Pathway Interactions
| Pathway | Interaction |
|---------|-------------|
| Alpha-synuclein aggregation | Triggers microglial activation; spread via neuroinflammation |
| Mitochondrial dysfunction | Source of ROS; activates NLRP3 |
| GBA/lysosomal pathway | Impairs autophagy; increases inflammatory burden |
| Oxidative stress | Amplifies inflammatory response |
| Excitotoxicity | synergizes with inflammation |
Microglial Heterogeneity in PD
The traditional M1/M2 classification of microglia is an oversimplification. Modern single-cell studies have revealed substantial microglial heterogeneity in PD, with distinct populations emerging in different disease stages and brain regions [@bhang2024].
Disease-Associated Microglia (DAM)
Disease-associated microglia represent a spectrum of activation states:
Early DAM: Characterized by upregulation of MHC molecules and complement components
Late DAM: Show increased expression of lipid metabolism genes and iron handling
Iron-associated microglia: Accumulate iron and show oxidative stress markersThe Human Microglia Atlas (HuMicA) has identified disease-specific microglial subsets that may serve as therapeutic targets [@martinsferreira2025].
Regional Microglial Variation
Microglial responses vary across brain regions:
- Substantia nigra: Highest density of activated microglia, reflecting ongoing neurodegeneration
- Striatum: Moderate activation, correlates with dopaminergic terminal loss
- Cortex: More variable, particularly in regions with Lewy bodies
- Brainstem: Early involvement in prodromal stages
TREM2 and Microglial Dysfunction
TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) variants are associated with increased PD risk, highlighting the importance of microglial phagocytosis in disease pathogenesis [@zhang2024].
TREM2 Signaling
TREM2 activates through interaction with ligands including:
- Apolipo (ApoE, ApoJ)
- Phospholipids on apoptotic cells
- Alpha-synuclein aggregates
TREM2 Variants and PD Risk
Certain TREM2 variants increase PD risk by:
- Impairing microglial phagocytosis
- Reducing clearance of alpha-synuclein
- Enhancing inflammatory responses
- Affecting lipid metabolism
Therapeutic Targeting
TREM2-targeting strategies include:
- Agonistic antibodies to enhance phagocytosis
- Small molecule modulators
- Gene therapy approaches
Astrocyte Involvement
While microglia dominate the neuroinflammatory conversation, astrocytes play crucial supporting roles [@chen2024].
Reactive Astrocytes in PD
Astrocytes undergo characteristic changes in PD:
A1 phenotype: Pro-inflammatory astrocytes that complement microglial responses
A2 phenotype: Potentially neuroprotective, associated with tissue repair
Senescent astrocytes: Lose supportive functions and release inflammatory mediatorsAstrocyte-Neuron Interactions
Astrocytes contribute to neuroinflammation through:
- Cytokine and chemokine release
- Complement component synthesis
- Glutamate uptake impairment
- Potassium buffering dysfunction
- Metabolic support loss
Astrocyte-Targeting Therapies
Emerging approaches include:
- Modulation of astrocyte reactivity
- Enhancement of neuroprotective phenotypes
- Restoration of glutamate handling
- Metabolic support strategies
The Gut-Brain Axis in PD
PD pathogenesis involves bidirectional communication between the gut and brain, with neuroinflammation as a key mediator [@li2024].
Gut Dysfunction in PD
- Alpha-synuclein pathology in enteric nervous system precedes brain involvement
- Intestinal permeability allows bacterial products to enter circulation
- Gut microbiome alterations correlate with disease severity
Peripheral Inflammation to Brain
Peripheral inflammatory signals reach the brain through:
- Vagus nerve: Direct neural connection to brainstem
- Circumventricular organs: Lack blood-brain barrier
- CVO penetration: Cytokines access parenchyma
- Endothelial activation: Enhanced BBB permeability
Clinical Implications
Evidence supports the gut-brain connection:
- Constipation predates motor symptoms by years
- Gastrointestinal inflammation correlates with PD severity
- Microbiome modulation affects motor symptoms
- Anti-inflammatory treatments show variable efficacy
Systemic Inflammation and PD
Beyond the CNS, systemic inflammation drives PD progression [@smith2024]:
Elevated Systemic Inflammatory Markers
- CRP (C-reactive protein)
- IL-6 (Interleukin-6)
- TNF-α (Tumor necrosis factor alpha)
- Soluble adhesion molecules
Sources of Systemic Inflammation
- Chronic infections
- Autoimmune conditions
- Gut permeability
- Environmental exposures
Implications for Therapy
Systemic inflammation provides:
- Biomarkers for disease progression
- Therapeutic targets outside the brain
- Prevention opportunities
| Biomarker | Sample | Level in PD |
|-----------|--------|-------------|
| TNF-α | CSF, plasma | Elevated |
| IL-1β | CSF, plasma | Elevated |
| IL-6 | CSF, plasma | Elevated |
| NfL | Plasma | Elevated |
| YKL-40 | CSF | Elevated |
| sTREM2 | CSF | Variable |
Emerging include:
- GFAP: Astrocyte activation marker
- MCP-1: Monocyte chemoattractant
- IP-10: IFN-γ-inducible protein
Mermaid diagram (expand to render)
Future Research Directions
Key Areas of Investigaention in prodromal stages
See Also
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway)
- Alpha-Synuclein Aggregation Pathway
- [LRRK2 Pathway](/mechanisms/lrrk2-pathway)
- Dopaminergic Neuron Selective Vulnerability Pathway
- NLRP3 Inflammasome Pathway - Biomedical literature
- Alzheimer's Disease Neuroimaging Initiative - Research data
- Allen Brain Atlas - Brain gene expression data
- Michael J. Fox Foundation - PD research resources
- Parkinson's Foundation - Patient education
Recent Research Updates (2024-2026)
Recent publications highlighting key advances in this mechanism:
- Chen et al., Potential biofluid markers for cognitive impairment in Parkinson's disease (2026)
- Jo et al., Hidden face of Parkinson's disease: Is it a new autoimmune disease? (2026)
- Jahan et al., Neuronal plasticity and its role in Alzheimer's disease and Parkinson's disease (2026)
- She et al., Emerging role of microglia in the developing dopaminergic system: Perturbation by early life stress (2026)
- Wang et al., Copper homeostasis and neurodegenerative (2025)
- Heneka et al., Neuroinflammation in Alzheimer disease. Nat Rev Immunol (2025)
- Martins-Ferreira et al., The Human Microglia Atlas (HuMicA) unravels changes in disease-associated microglia subsets (2025)
- Fang et al., Glucose Metabolic Reprogramming in Microglia (2025)
- Liu et al., LRRK2 Mediates alpha-Synuclein-Induced Neuroinflammation and Ferroptosis (2025)
- Bhang et al., Microglial heterogeneity in Parkinson disease (2024)
- Zhang et al., TREM2 polymorphisms and Parkinson disease risk (2024)
- Chen et al., Astrocyte reactivity in Parkinson disease (2024)
- Wang et al., NLRP3 inflammasome inhibition in Parkinson disease (2024)
- Li et al., Gut-brain axis in Parkinson disease (2024)
- Smith et al., Peripheral inflammation and PD progression (2024)
References
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Unknown (n.d.)
Chen J et al., Potential biofluid markers for cognitive impairment in Parkinson's disease. Neural Regen Res (2026)
Jo MG et al., Hidden face of Parkinson's disease: Is it a new autoimmune disease? Neural Regen Res (2026)
Jahan I et al., Neuronal plasticity and its role in Alzheimer's disease and Parkinson's disease. Neural Regen Res (2026)
She K et al., Emerging role of microglia in the developing dopaminergic system. Neural Regen Res (2026)
Wang Y et al., Copper homeostasis and neurodegenerative . Neural Regen Res (2025)
Tansey MG et al., Neuroinflammation in Parkinson's disease (2022)
Wang B et al., NLRP3 inflammasome activation in Parkinson's disease (2021)
Kouli A et al., Parkinson's Disease: Cause and Treatment. Curr Neurol Neurosci Rep (2018)
Heneka MT et al., Neuroinflammation in Alzheimer disease. Nat Rev Immunol (2025)
Martins-Ferreira R et al., The Human Microglia Atlas (HuMicA). Nat Commun (2025)
Fang M et al., Glucose Metabolic Reprogramming in Microglia. Mol Neurobiol (2025)
Guenoun D et al., Microglial Depletion: Comparison of Pharmacological Inhibitors of the CSF-1R. Glia (2025)
Carr L et al., The Hallmarks of Ageing in Microglia. Cell Mol Neurobiol (2025)
Liu X et al., LRRK2 Mediates alpha-Synuclein-Induced Neuroinflammation and Ferroptosis. Proc Natl Acad Sci (2025)
Tsafaras G et al., The G2019S LRRK2 mutation exacerbates alpha-synuclein and tau neuropathology. Acta Neuropathol (2025)
Wang J et al., Longitudinal decline in striatal DAT binding in LRRK2 Parkinson's disease. Mov Disord (2025)
Bhang MK et al., Microglial heterogeneity in Parkinson disease: implications for targeted therapies (2024)
Zhang L et al., TREM2 polymorphisms and Parkinson disease risk (2024)
Chen Q et al., Astrocyte reactivity in Parkinson disease: from to therapeutic targets (2024)
Wang X et al., NLRP3 inflammasome inhibition as a therapeutic strategy in Parkinson disease (2024)
Li Y et al., Gut-brain axis in Parkinson disease: neuroinflammation links (2024)
Smith A et al., Peripheral inflammation and PD progression: a meta-analysis (2024)